 This randomized, double-blind clinical trial will examine the effectiveness of extended release DVP Depakote-ER in the treatment of co-morbid mood and anxiety disturbance in alcohol dependent subjects. The primary hypothesis is that subjects treated with Depakote-ER will have significantly lower scores on the Symptom Checklist SCL-90-R than will placebo treated subjects over the course of the study. Secondary hypotheses include: 1 Compared to placebo treated subjects, subjects treated with Depakote-ER will demonstrate significantly lower scores on additional measures of depression, anxiety, and irritability, 2 will have fewer alcohol use days and fewer drinks per drinking day, and 3 will evidence better retention in alcohol dependence treatment. 